BEVA President, Madeleine Campbell will be announcing plans for a veterinary-led European Transport Forum at BEVA Congress this year (8-11 September 2010), to discuss how the welfare of horses during transport can be improved through the better enforcement of legislation.

Dr Campbell is also the British Veterinary Association representative on the Federation of Veterinarians of Europe (FVE) working party for transport. The Forum, which will be held in Brussels on 29 November 2010, has been jointly organised by the FVE and BEVA and is sponsored by World Horse Welfare (WHW). It is hoped that it will be attended by over 150 participants, including representatives of EU Member States, CVOs, Members of the European Commission and European Parliament, scientific experts, national veterinary organisations, animal transport associations and animal welfare associations.

The Forum will review the enforcement of the existing European regulations that currently govern the transport of horses for slaughter and for other purposes. Areas for practical improvement will be identified with the key focus on the enforcement of current legislation and the role of vets in ensuring that the welfare of horses in transit is protected. The conference will endeavour to define the critical control points, effective control systems and good practices. It will also look into trade flows, animal health risks, horse identification and the effects of closing horse slaughterhouses.

Dr Campbell said: "It is all very well to campaign for new regulations but at present even the existing regulations are not being enforced adequately. The crux of the matter is enforcement and there are none better placed to help with this than vets. If we can all work collectively we should have the strength to make a real impact. This is what the Forum is about."

Dr Campbell will be speaking about the European Transport Forum at the Congress press conference on 10 September between 9am and 10am.

BEVA Congress runs from 8-11 September 2010 at the International Convention Centre, Birmingham. For further information and to register visit http://www.beva.org.uk/

CEVA Animal Health has published a trial which, according to the company, shows that horses suffering lameness caused by bone spavin can show marked improvement following treatment with a Tiludronate infusion, in combination with controlled exercise.

Bone spavin is a chronic aseptic osteoarthritis of the distal tarsal joints which, says CEVA, is considered to be one of the most common forms of hindlimb lameness in the horse.

The double-blind, multicentric, placebo-controlled trials were carried out on a total of 108 pleasure horses, show jumpers and eventers of a variety of sizes and breeds, all of which had been clinically diagnosed with bone spavin. The horses were rigorously selected, having to show clinical signs of spontaneous lameness of at least six weeks but less than a year's duration and had to be in daily exercise. Horses suffering proximal suspensory desmitis were excluded.

Horses were defined as suffering from bone spavin if they displayed a chronic hindlimb lameness which improved with distal tarsal joint analgesia and showed radiographic evidence of bony changes associated with bone spavin in the distal tarsal joints. The horses were treated at day zero with a single Tiludronate infusion or a placebo and reassessed 60 days later after a period of controlled exercise.

Eighty seven horses completed the trials, comprising 42 Tiludronate treated horses and 45 placebo cases. By day 60 approximately 60% of the Tiludronate treated horses had improved in lameness by two grades or more, scored on a ten point system.

Horses with bone spavin experience abnormal bone remodeling changes, occasionally with excessive bone resorption in the tarsal bones. Tiludronate works by regulating this bone remodeling through a decrease in the resorptive process, slowing down the degradation of the bone structure when the condition is progressing and alleviating the pain associated with abnormal bone lysis.

CEVA has recently produced a leaflet specifically to help horse owners to understand the diagnosis and treatment of bone spavin. For copies of this leaflet and CEVA's comprehensive veterinary brochure on the product please contact CEVA Animal Health on 01494 781510 or visit the website at http://www.tildren.com/

Tiludronate infusion in the treatment of bone spavin: A double blind placebo-controlled trial

Reference 
M. R. GOUGH*, D. THIBAUD† and R. K. W. SMITH‡ (*CEVA Animal Health, Bucks, UK; †CEVA Animal Health USA, Kansas, USA; and ‡Department of Veterinary Clinical Sciences, The Royal Veterinary College, University of London, UK). Equine vet. J. (2010) 42 (5) 381-387 doi: 10.1111/j.2042-3306.2010.00120.x

Dechra Veterinary Products has launched free online Fluid Therapy Calculators to help veterinary staff calculate their patients' fluid requirements.

There are two versions available, small animal and equine. Both are available as an online tool or as a download to your desktop (note that to get hold of the desktop version, you need to try out the online calculator first). 

For small animals, there are three options available. The M1/M2/M3 Plan calculates simple multiplications of the maintenance rate, while the Comprehensive Plan calculates fluid required to provide maintenance requirements, correct dehydration or replace ongoing losses. The third option, the Simple Rate Calculator, is a tool for calculating resuscitation fluid rates and can also be used for large animals. The Equine Plan calculates fluid requirements and infusion rates for both adult horses and foals.  

Dechra says it has launched the calculators as the next component of its Vetivex Fluid support package. Along with the Fluids Knowledge Programme, this initiative aims to help veterinary staff across the UK to deliver effective fluid therapy. 

Larry King, Product Manager at Dechra, said: "The calculators are a quick and easy reference tool for today's busy vet. You simply fill in the body weight and animal type, key in a few details and you have an instant but very accurate fluid rate calculated for you. It saves time and effort and ensures the animal is given the correct amount of fluid. The more effective the fluid therapy regime the faster the animal recovers."

The free Fluid Therapy Calculator is just one of a number of tools Dechra uses to support its Vetivex range of fluids.  There is a range of downloadable reference documents, charts and guides available on the website http://www.fluidtherapy.co.uk/ including the Fluid Knowledge Programme and a full CPD Programme focused on effective fluid therapy.

Intervet/Schering-Plough Animal Health has announced that it is re-introducing Equilis StrepE, the only strangles vaccine for horses in Europe. The vaccine was voluntarily withdrawn from the market in 2007 for stability reasons.

Equilis StrepE, which has already been relaunched in the Netherlands, is now scheduled to arrive in Italy in September and the United Kingdom in October this year. Further re-launches in European countries are scheduled later in 2010 and beyond.

According to Intervet/Schering-Plough, three years of additional research and development have resulted in several improvements to the vaccine, including a better manufacturing process to ensure that the product maintains its characteristics throughout its shelf-life. A more user-friendly applicator has been developed, which enables the needle to slot into place, thereby making it easier to administer the vaccine.

Equilis StrepE is administered through a submucosal injection in the upper lip of the horse and provides immunity for three months following two initial injections, four weeks apart. The vaccine significantly reduces clinical signs of strangles and occurrence of lymph node abscesses in horses that are at risk of infection.

Dr. Peter Daels, veterinarian at the Keros Insemination and Embryo Transfer Center in Beselare (Belgium) said: "In our recipient embryo transfer herd, we have used this strangles vaccine on over 500 mares. After a few applications, the vaccine was easy to administer and did not cause any serious side effects. Despite a steady flow of new horses, only eight cases of strangles were noted - all were mild and most were newly acquired horses that had apparently been exposed shortly before vaccination. I believe that the vaccine provided solid protection against the disease, reduced the severity of clinical cases and eliminated the risk of a widespread outbreak in our herd."

Dr. Roberto Ragni-Alunni, Global Technical Manager Equine at Intervet/Schering Plough Animal Health said: "The re-launch of Equilis StrepE in Europe is an important milestone in our efforts to fully meet the needs of our customers in the equine industry. We continue to work in a very intense and comprehensive way to ensure adequate supply of our equine vaccine range". 

Alstoe Animal Health has introduced a new, palatable joint nutrient supplement for horses.

According to the company, the benefits of feeding equine joint nutrient supplements to assist with maintaining mobility and supporting health joint function has been well documented, but until now, their flavours have often had to be disguised by mixing them into the feed in an attempt to ensure compliance.

Easeflex Equine palatable pellets include alfalfa, an equine favourite which has been used in the USA for some time, and shown to be readily accepted by horses, without the need to mix with the feed.

Alstoe says Easeflex Equine contains high levels of glucosamine hydrochloride and chondroitin sulphate, which are important in the production of glycosaminoglycans, and which have chondroprotective properties that aid in the natural renewal of cartilaginous tissue. Easeflex Equine palatable pellets also include MSM (methyl-sulphonyl-methane), a source of bioavailable sulphur, a key component of connective tissue and important in the synthesis of articular cartilage. Antioxidants are also present to help prevent damage by free radicals, as well as the essential trace minerals, copper, zinc and manganese.

Easeflex Equine palatable pellets can be fed to horses, ponies and donkeys of any age. The company recommends initial daily feeding of a double loading quantity for the first four to six weeks, thereafter reducing to a maintenance level or as directed by the veterinary surgeon. The amount of pellets to be fed depends on the weight of the animal, one small scoop containing 28g of pellets can be a daily dose for a horse of up to 450kg. Easeflex Equine palatable pellets are available in 1.7kg and 4.54kg tubs.

From 1st March vets can sign up to be alerted to all recorded equine influenza cases in the UK, thanks to a new service from the Animal Health Trust (AHT) and Merial Animal Health.

Tell Tail is the UK's first equine influenza (EI) text alert service exclusively for equine vets, set up to provide practices and their clients with what could be invaluable information in the face of a potential outbreak. 

Dr Emma Batson from Merial said: "Vets will be notified of an EI outbreak within 48 hours of confirmed diagnosis. Not only will this allow them to alert their clients, but we believe that it will also help to encourage horse owners to become more compliant with vaccination schedules.

"Currently it is estimated that only a third of the UK horse population is vaccinated for EI. This situation is not only a potential welfare issue, but it also provides practices with a significant opportunity to increase the number of horses protected against EI, resulting in a win-win situation for all."

Dr Richard Newton, Head of Epidemiology and Disease Surveillance at the AHT, believes the text alert service will also help improve awareness and knowledge of EI, and he hopes all equine vets will sign up for the scheme. He said: "We believe that the launch of the alert service for vets marks an important step in the quest to help minimise the risk of an EI outbreak in the UK.

"EI doesn't have a carrier state, which means that it never goes away and re-emerges, instead it circulates continuously. So without continued surveillance we could easily lose track of it.

"We hope that as well as allowing practices to track and respond to outbreaks in their area, the alerts will also encourage vets to send in samples from animals with cold and flu-like symptoms. This is a free service which in turn provides us with more information to circulate within the industry, allowing everyone to be more effective at managing the disease.

"Vaccination is our best defence against EI, but to remain effective the World Organisation for Animal Health (OIE) Expert Surveillance Panel, needs to make any update recommendations based on the latest position in the field. And this information can only be gathered via effective surveillance."

Dr Batson agrees and hopes that the combination of the Tell Tail text alert service and surveillance scheme will help to reduce the risk of an outbreak occurring in the UK. She said: "In the UK we continue to see regular confirmed outbreaks of EI, so we can never afford to become complacent about the risks.

"You only have to look at the relatively recent major outbreaks in Australia, South Africa, India and China, to see the devastating effects which can ripple throughout equine industries, both in financial as well as welfare terms."

Tell Tail is a free service. To register your interest, text your name, practice and postcode to 07797 801863. Alternatively, visit http://www.merial.com/ and click on the Tell Tail link, or speak to your Merial territory manager.

The National Association of Veterinary Physiotherapists (NAVP) is calling for the Royal College of Veterinary Surgeons (RCVS) to establish an independent register of veterinary physiotherapy practitioners. According to the Association, such a register would eliminate individuals practicing without proper training and qualifications and raise the standard of veterinary physiotherapy by providing a disciplinary role.

NAVP President and leading veterinary anatomist Dr Sue Kempson is heading the NAVP campaign for the establishment of an independent register. In a letter to the President of the RCVS, Dr Kempson said: "Recognition by the veterinary profession of the role of physiotherapy in post-operative rehabilitation and in supporting both companion and performance animals is growing. However, we do believe that referring veterinary surgeons are increasingly faced with a dilemma caused by the wide differential between qualifications offered by the various organisations representing practitioners in areas such as physiotherapy. There is an urgent need for a distinction to be made between these different types of qualification. To this end, there should be a clearly defined independent register of practitioners with appropriately validated qualifications which are clearly understood by the veterinary profession."

In partnership with Harper Adams University College, the NAVP has introduced a fully-validated post-graduate course in veterinary physiotherapy which offers a choice of Post-Graduate Diploma or Masters Degree. Only one other professional body, the Association of Chartered Physiotherapists in Animal Therapy (ACPAT) currently offers a similar qualification at this level.

Dr Kempson said: "The establishment of a register of physiotherapists would greatly assist vets and their clients to make informed decisions on their choice of therapist. It would eliminate those individuals without proper training and qualifications and help raise the standard of veterinary physiotherapy by providing a disciplinary role. At present there are no sanctions on those people practicing without the necessary qualifications or those whose work is sub-standard or who are guilty of professional misconduct.

"We do not believe that such a register should rest with any individual professional body or be affiliated to specific educational courses. To have authority, it requires independence and a register held under the auspices of the Royal College of Veterinary Surgeons would carry the credibility that the veterinary profession requires."

Practices will be able to offer customers increased support for their worming programmes in 2010, as part of a new initiative from Eqvalan® manufacturer, Merial.  

Eqvalan product manager Claire Edmunds said: "The SMART worming campaign is designed to encourage owners to Simply Monitor, Assess Risk and, if necessary, Treat with the most appropriate wormer.

"We know that worming can be confusing for horse owners, so the SMART approach is designed to help them manage their worming programmes more easily, whilst also ensuring that wormers are used in a way that may help prevent the development of resistance.

Practices purchasing Eqvalan Duo during February and March can get 4 tubes free when they purchase 20. In addition, to kick start the SMART campaign for each order on the above offer, Merial will supply 20 free Worm Egg Count vouchers worth £10/€10 each. For those practices with their own testing facilities, the company is also offering promotional support to help encourage increased uptake and client buy-in.

Claire added: "As well as continuing with the successful free worm egg count campaign available for practices during February and March, owners will also have access to a personalised on-line planner, as well as text and email alerts.

"The campaign is being supported with new point of sale material and a prominent consumer advertising campaign. In addition we also have an extensive VN SQP CPD training programme planned for 2010. 

"With the consensus of expert opinion on the future of worming firmly behind the use of targeted programmes incorporating worm egg counts, there has never been a more important time to get closer to clients and help them with their worming strategies."  

If you would like further information, please contact your local territory manager or call the Merial Customer Support Centre on 0845 601 4236. 

Intervet/Schering-Plough Animal Health has reported that since launch, its diagnostic service RespCheck has identified infectious diseases in 15 per cent of all animals checked under the scheme.

Offered to qualifying practices for no charge and implemented by the Animal Health Trust (AHT), Intervet/Schering Plough set up RespCheck to help identify the cause of infectious respiratory problems in horses.

The RespCheck kit, which has been used to swab more than 700 horses since launch, consists of naso pharyngeal swabs, enabling two horses per yard or outbreak to be swabbed for a variety of diseases.  These include equine influenza, equine herpesvirus, Streptococcus equi (strangles), pasteurella, rhinovirus and Streptococcus zooepidemicus.  The swabs are sent to the AHT for analysis and the results returned direct to the vet.

John Dickerson from Chine House Equine Hospital in Leicestershire said: "The service is fantastic, made all the better by being completely free of charge! The benefits are two-fold. From the clinical perspective it means we can discount or treat potential infections in a more timely fashion; for instance, we use RespCheck to screen for any suspected infectious respiratory disease cases which enables us to deal with the problem, through quarantine and strict hygiene measures, helping to prevent the spread of the disease.

The other benefit is to our practice reputation and the standard of service we can offer. It's great to be able to provide owners with peace of mind without it costing more than our call out fee. By the time an owner calls the vet they are usually stressed and worried about their horses symptoms and need some reassurance, which is exactly what RespCheck gives them. We are confident that  providing a diagnostic service that is completely free and that puts an owners mind at rest regarding the risk of an infection can only be a good thing for our practice reputation and customer care.

Last year, the service proved its worth when the screening of a recently imported horse showed the animal had equine influenza. I believe that had RespCheck not been employed, we would have had an outbreak in that particular yard."

Practices interested in knowing more about RespCheck should contact their local Intervet/Schering-Plough Veterinary Business Manager or phone the company's Veterinary Support Group on 01908 685685.

A research project funded by equine charity The Horse Trust has succeeded in killing equine sarcoid cells in vitro by silencing a gene in the virus that causes sarcoids. The researchers are now hoping to obtain funding for clinical trials using the new technique, which could result in a more effective, non-toxic treatment for sarcoids.

Sarcoids are skin tumors caused by infection with the Bovine Papillomavirus (BPV). They are the most common type of tumour found in horses - the estimated prevalence in the UK is 6-7%. Although the disease is rarely life threatening, many horses with sarcoids are euthanased because the condition is untreatable or because the horse is unsellable. Currently there is no universally effective treatment for sarcoids and if treatment fails the sarcoids will often come back worse.

However, research that was given funding by The Horse Trust offers a potential ray of hope for owners of horses affected by sarcoids. The research was published in Virus Research journal earlier this year.

The research, which was led by Professor Lubna Nasir of the University of Glasgow, found that by inhibiting the activity of a particular viral protein within sarcoid cells, the amount of viral DNA in the cells reduced. This led to a reduction in the growth of the sarcoid cells and caused the cell to die by Programmed cell-death (PCD). The researchers believe that PCD occurs because the sarcoid cells become reliant on the virus.

Professor Nasir said: "This could potentially be a major breakthrough in the treatment of sarcoids. We are now seeking funding to use this technique in clinical trials on horses that have sarcoids."

The research team inhibited the activity of a viral protein called E2, which is needed by BPV to replicate. They used a novel approach termed 'gene silencing' to suppress the activity of the gene that codes the E2 protein. The research was carried out in vitro on fibroblast cells, which had been cultured from sarcoid tissue removed from animals during surgery.

As this research was carried out in vitro, the researchers will now need to see if they can replicate the results in vivo, by developing a way of targeting the sarcoid cells in horses.

"One of the challenges with gene silencing is administering it within clinical setting - as you need to get molecules into every cell. As sarcoids are on the surface of a horse, we think administration should be relatively easy - potentially by injecting or applying a cream to the sarcoid," said Professor Nasir. "If we are able to successfully develop this technique it would be a non-toxic and easy to administer treatment for horses affected by this distressing condition."

Nasir's research could also have an impact on the treatment of lesions in cattle, which are also caused by BPV. Around 50% of cattle in the UK are estimated to have lesions. It may also help with the treatment of Human Papillomavirus (HPV) infections in humans. HPV, which is similar to BPV, can lead to various cancers in humans including cervical and vaginal cancer.

Paul Jepson, Chief Executive and Veterinary Director of The Horse Trust said: "We are really excited that the research we have funded could lead to a major breakthrough in the treatment of sarcoids."

Research amongst veterinary surgeons by Janssen Animal Health, maker of Cavalesse oral and Cavalesse topical, has revealed that owners could be doing more harm than good when it comes to managing sweet itch in their horses.

92% of vets questioned are aware that people follow old wives' tales by administering lotions and potions such as garlic and olive oil to ward off flies during the summer sweet itch season, when garlic actually has the opposite effect of attracting them.

According to Janssen, it is thought that only a quarter of horse owners are aware that it is important to carry out preventative measures before the start of the midge season to help alleviate sweet itch. 14% of people are thought to go to their vet for advice on sweet itch, while 30% seek help from their country store or tack shop, 27% search for information on websites and 26% ask other horse owners for guidance. This is despite the fact that 92% of those questioned believe that sweet itch would clear up quicker if people sought advice from their veterinary surgeon.

Nicki Glen, marketing manager at Janssen Animal Health said: "Sweet itch can be an incredibly difficult and frustrating condition to manage, however horse owners do not tend to seek advice from their vets. It is therefore important to educate horse owners while you are on yard visits with pro-active advice on the condition for the long-term health and welfare of horses."

Cavalesse is a natural food supplement containing a specialised formulation of water-soluble vitamins and minerals, including nicotinamide.  Once a month the contents of each sachet are dissolved in water to form an oral solution, which can be administered daily via a special pipette, either by sprinkling over a small handful of feed or adding to a treat such as a sugar lump.  Janssen says the supplement helps horses maintain a healthy skin and promotes normal immune function in horses prone to summer allergies.

Cavalesse Topical is a skincare gel that can be used in combination with the Cavalesse solution.  The gel can be applied to the skin to help support natural immunity from the outside, whilst the oral solution works in partnership from the inside.

For further information on Cavalesse and Cavalesse Topical please contact your Janssen Animal Health account manager or phone 01494 567555.

Gil Riley of the Pool House Veterinary Hospital in Lichfield, Staffordshire has won the annual Petplan Equine Vet of the Year Award. 

The Award was announced at the 21st annual Animal Health Trust (AHT) Equestrian Awards gala dinner held at the Lancaster Hotel in London last Thursday.

Horse owners from all over the UK nominated vets who had gone above and beyond the call of duty. A short list of three finalists was then drawn up and the winner selected by an independent panel consisting of: Peter Webbon AHT Chief Executive and Equine Vet, Alison Bridge Editor-in-Chief of Horse & Rider Magazine, Chris House President of the British Equine Veterinary Association (BEVA) and Jo Whitaker Marketing Development Manager for Petplan.

Peter Webbon of the AHT said "We received a record number of nominations this year and the standards were incredibly high.  However, Gil was nominated by over 100 clients and we felt he was truly deserving of this award."

Alison Andrew, Marketing Manager for Petplan said: "This award recognises the amazing hard work and commitment of people within the equine veterinary profession and those who provide outstanding service to horse owners."

Gil joined the Pool House Veterinary Group and Equine clinic practice to expand his equine skills after working in a mainly agricultural practice in Wales and is jointly responsible for the Equine part of the Practice. He has subsequently been awarded the Royal College of Veterinary Surgeons Certificate in Equine Practice and he is particularly interested in lameness and laminitis.  He also recently acted as British Team Vet at the International Driving Trials in Germany.

Gil said: "Everyday I feel like I'm pulling the greatest trick in that I get paid for doing what I love. To receive further recognition with this award almost feels greedy. I'm tremendously flattered and indebted to all my clients who nominated me."

In his acceptance speech Gil praised his team for their dedication and support without whom, he said this would not have been possible. Special thanks went to his proud wife Emma on the evening of their fifth wedding anniversary.

The Animal Health Trust Equestrian awards are designed to recognise the outstanding achievements made by horses, riders, owners and trainers throughout the equestrian world. Since the Petplan Charitable Trust was founded in 1994 it has raised over £5million, almost £500,000 of which has been donated to the AHT to fund research and development.